Compare Incyte Corporation (INCY) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sea Limited — how do they compare? Incyte Corporation trades at $121.39 (market cap $24.54B), while Sea Limited trades at $128.19 (market cap $80.55B). The key difference: Sea Limited is far larger — about 3.3× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| INCY | SE | |
|---|---|---|
Market Cap | $24.54B | $80.55B |
Sector | Health | Media |
52-Week High | $129.93 | $196.50 |
52-Week Low | $81.61 | $78.16 |
Enterprise Value | $20.04B | $75.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Sea Limited (SE) trades at $114.80, up 1.21% with strong technical momentum as the stock approaches key resistance levels. The company demonstrates robust fundamental growth with Q2 2026 revenue of $7.8 billion (up 48% YoY) and net income growth of 11%, supported by diversified performance across e-commerce, fintech, and gaming segments. Analyst consensus remains strongly bullish with a $128.33 price target, though valuation metrics appear elevated with a P/E of 50.78.
SE presents compelling growth prospects with accelerating revenue and expanding profitability, but faces risks from increased investment spending and competitive pressures. The stock's current technical overbought condition near resistance suggests potential near-term consolidation before further upside. Wall Street's overwhelming buy rating (70% of analysts) supports the positive long-term outlook despite premium valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
